On June 15, 2017 Seattle Genetics, Inc. (Nasdaq: SGEN) and Bristol-Myers Squibb Company (NYSE: BMY) reported an updated interim analysis from the ongoing phase 1/2 clinical trial evaluating ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory (RR) classical Hodgkin lymphoma (HL) at the International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland (Press release, Bristol-Myers Squibb, JUN 15, 2017, View Source [SID1234519549]). The data reported from 62 patients, including 59 evaluable for response, will be featured in an oral presentation on June 15, 2017. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL. Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to help restore anti-tumor immune response. ADCETRIS and Opdivo are not approved in combination for the treatment of RR classical HL or for other indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The phase 1/2 study combining the antibody-drug conjugate brentuximab vedotin with the PD-1 immune checkpoint inhibitor nivolumab is a promising investigational approach as it combines a targeted therapy with a therapy designed to activate the immune system and the combination may have additive activity," said Alex Herrera, M.D., lead trial investigator and assistant professor at the City of Hope, Duarte, California. "The interim results support further exploration of this novel regimen, free of traditional chemotherapy."

"We are evaluating ADCETRIS in novel combinations in order to identify potential treatment regimens for patients with CD30-expressing lymphomas," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development of Seattle Genetics. "We are pleased to share updated interim results from this ongoing phase 1/2 clinical trial evaluating ADCETRIS in combination with Opdivo in relapsed or refractory HL patients. Since our first patient treated with the combination regimen, the data continue to demonstrate encouraging activity with an acceptable safety profile. These updated data support findings first presented at ASH (Free ASH Whitepaper) 2016. We have nearly doubled the number of patients in our trial evaluating the ADCETRIS/Opdivo combination strategy and recently announced a collaboration with BMS to initiate a pivotal phase 3 clinical trial in relapsed HL patients in mid-2017."

"Bristol-Myers Squibb continues to strengthen our broad Immuno-Oncology and hematology development programs for Opdivo," said Fouad Namouni, M.D., head of Oncology Development, Bristol-Myers Squibb. "Our continued partnership with Seattle Genetics, combines our deep I-O experience and shared commitment to innovative combination treatment options that have the potential to improve the lives of patients impacted by blood cancers. We look forward to further evaluation of ADCETRIS in combination with Opdivo for the treatment of relapsed Hodgkin lymphoma."

Interim Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma (Abstract #074, oral presentation at 6:05 p.m. CEST)

Data were reported from 62 patients with RR classical HL after failure of frontline therapy who received the combination regimen of ADCETRIS plus Opdivo. Patients were treated once every three weeks with up to four cycles of combination therapy. After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 36 years. Forty-five percent of patients had primary refractory disease and 55 percent progressed after responding to frontline therapy, among whom 90 percent received standard of care frontline treatment ABVD (Adriamycin, bleomycin, vinblastine and dacarbazine).

Key findings presented include:

Of 59 response-evaluable patients, 50 patients (85 percent) had an objective response, including 37 patients (63 percent) with a complete response and 13 patients (22 percent) with a partial response. Five patients (eight percent) had stable disease and four patients (seven percent) had progressive disease.
Of the 62 patients enrolled, 61 patients (98 percent) received one or more dose of the study therapies. No patients remain on treatment, 58 patients (94 percent) have completed treatment and four patients (six percent) discontinued prior to the end of treatment. At the time of data analysis in the ongoing trial, 37 patients (60 percent) initiated an ASCT and 12 patients (19 percent) received an alternative salvage therapy subsequent to combination therapy. No unusual post-ASCT adverse events were reported. Preliminary analysis shows no impact of ADCETRIS and Opdivo combination on stem cell mobilization or engraftment.
Prior to ASCT, the most common adverse events of any grade occurring in more than 25 percent of patients were nausea (56 percent); fatigue (43 percent); infusion-related reactions (IRRs, 36 percent); pruritus (31 percent); headache (28 percent); and diarrhea, rash and vomiting (all at 26 percent). Treatment-related serious adverse events occurred in five patients (eight percent), including pneumonitis and pyrexia (two patients each) and colitis, malaise, nausea, pneumonia, respiratory failure and sepsis (one patient each).
Infusion related reactions (IRRs) were observed in 41 percent of patients. All IRRs were Grade 3 or less, with the rate of Grade 3 IRRs less than five percent.
ADCETRIS and Opdivo are being evaluated as combination therapy in multiple ongoing clinical trials. In addition to the study presented at ICML, a pivotal phase 3 clinical trial evaluating ADCETRIS in combination with Opdivo compared to ADCETRIS alone in relapsed/refractory HL patients is planned to begin enrollment in mid-2017. In addition, a trial titled "A Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas" is ongoing and focused on patients with relapsed or refractory disease, including diffuse large B-cell lymphoma (DLBCL), and other rare subtypes of B-cell, including mediastinal B-cell lymphoma and mediastinal gray zone lymphoma. The companies recently extended the clinical evaluation of ADCETRIS and Opdivo into a clinical trial evaluating the combination as frontline treatment for older HL patients.

About Classical Hodgkin Lymphoma

Lymphoma is a general term for a group of cancers that originate in the lymphatic system and is the most common type of blood cancer. There are two major categories of lymphoma: HL, also known as Hodgkin disease, and non-Hodgkin lymphoma. HL is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. The disease is most often diagnosed in early adulthood (ages 20-40) and late adulthood (older than 55 years of age). Classical Hodgkin lymphoma is the most common type of HL, accounting for 95 percent of cases. Classical HL is distinguished from other lymphomas by the characteristic presence of CD30-positive Reed-Sternberg cells.

According to the American Cancer Society, more than 8,000 cases of HL will be diagnosed in the United States during 2017 and approximately 1,000 will die from the disease. According to the Lymphoma Coalition, over 62,000 people worldwide are diagnosed with HL each year and approximately 25,000 people die each year from this cancer. In the European Union, about 12,200 new cases and 2,600 deaths occurred in 2012 as a result of HL.

About ADCETRIS

ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing Seattle Genetics’ proprietary technology. The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Seattle Genetics and Takeda are jointly developing ADCETRIS. Under the terms of the collaboration agreement, Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights to commercialize ADCETRIS in the rest of the world. ADCETRIS has received marketing authorization by regulatory authorities in 67 countries for relapsed or refractory HL and systemic anaplastic large cell lymphoma (sALCL). In addition, ADCETRIS is being evaluated broadly in more than 70 ongoing clinical trials, including three phase 3 studies, the ongoing ECHELON-1 trial in frontline classical Hodgkin lymphoma and the ongoing ECHELON-2 trial in frontline mature T-cell lymphomas, as well as the completed ALCANZA trial in cutaneous T-cell lymphoma for which a supplemental Biologics License Application is planned in mid- 2017. See important safety information below.

About Opdivo

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Opdivo’s leading global development program is based on Bristol-Myers Squibb’s scientific expertise in the field of Immuno-Oncology and includes a broad range of clinical trials across all phases, including Phase 3, in a variety of tumor types. To date, the Opdivo clinical development program has enrolled more than 25,000 patients. The Opdivo trials have contributed to gaining a deeper understanding of the potential role of biomarkers in patient care, particularly regarding how patients may benefit from Opdivo across the continuum of PD-L1 expression.

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 60 countries, including the United States, the European Union and Japan. In October 2015, the company’s Opdivo and Yervoy combination regimen was the first Immuno-Oncology combination to receive regulatory approval for the treatment of metastatic melanoma and is currently approved in more than 50 countries, including the United States and the European Union.

On June 15, 2017 CTI BioPharma Corp. (NASDAQ and MTA:CTIC) reported that it has received a $10 million milestone payment from Teva Pharmaceutical Industries Ltd. related to the achievement of sales milestones for TRISENOX (arsenic trioxide). TRISENOX was acquired from CTI BioPharma by Cephalon, Inc. (Cephalon) (Press release, CTI BioPharma, JUN 14, 2017, View Source [SID1234519550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under which CTI BioPharma is eligible to receive up to an additional $60 million in payments upon achievement by Teva of specified sales and development milestones related to TRISENOX.

On June 14, 2017 MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage immuno-oncology drug development company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer, reported results from its Phase 1 clinical trial of its ImmunoPET imaging agent, MVT-2163, for patients with locally advanced or metastatic adenocarcinoma of the pancreas (PDAC) or other CA19-9 positive malignancies (Press release, MabVax, JUN 14, 2017, View Source [SID1234519548]). Results from the Phase 1 clinical trial were presented in a poster session and podium talk at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in Denver, CO June 10-14, 2017.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster was presented by Joseph O’Donoghue, Ph.D., Associate Attending Physicist, Department of Medical Physics at Memorial Sloan Kettering Cancer Center and the podium talk was presented by Lars Guenter Christian Lohrmann, M.D., Assistant Member and Assistant Attending Radiologist at Memorial Sloan Kettering Cancer Center and the lead investigator in the MVT-2163 Phase 1 clinical trial. Both presentations summarized the Company’s Phase 1 clinical findings.

To date, twelve patients have been treated in this first-in-human trial evaluating the safety and feasibility of MVT-2163 to image pancreatic tumors and other CA19-9 positive malignancies. MVT-2163 was administered alone and in combination with MVT-5873, and was well tolerated in all cohorts. The only toxicities were infusion reactions that resolved on the day of the injection, with some requiring supportive medication.

Uptake of MVT-2163 was observed in primary tumors and metastases as early as day 2 and continuously through day 7. Standard Uptake Values (SUV), a measurement of activity in PET imaging, reached as high as 101 in the study. The investigators reported that the high SUV is amongst the highest lesion uptake they have ever seen for a radiolabeled antibody. Bone and soft tissue disease were readily visualized and lesion uptake of the radiotracer was higher than typically seen with PET imaging agents. The correlation with Computerized Tomography (CT) scans was high.

Results showed that MVT-5873 cold antibody pre-dose reduces liver SUV facilitating detection of liver metastases. In addition, the MVT-5873 cold antibody pre-dose does not interfere with the uptake of MVT-2163 on cancer lesions.

"We are delighted with the safety and quality of the PET images obtained with MVT-2163. The promising correlation with diagnostic CT warrants further studies correlating these findings with histopathology to assess the accuracy. The continual increase in high SUV values on cancer lesions in this study supports the use of the Company’s MVT-1075 Radioimmunotherapy product which utilizes the same antibody to deliver a radiation dose for the treatment of patients with pancreatic, lung and colon cancers. We anticipate initiating patient dosing of our MVT-1075 radioimmunotherapy trial later this month," commented David Hansen, President and CEO of MabVax Therapeutics.